“Increasing Prevalence of Viral Infections”
- A significant and accelerating trend in the antiviral drugs market is the rising prevalence of viral infections such as HIV, hepatitis B and C, influenza, and emerging viral threats including coronavirus strains, which is intensifying the global focus on antiviral therapy development
- For instance, the global burden of hepatitis B affects over 250 million people, while annual influenza epidemics result in millions of severe cases and hundreds of thousands of deaths, prompting urgent demand for effective antiviral treatments
- The increasing frequency of zoonotic spillovers and the global spread of contagious viruses are prompting healthcare systems and pharmaceutical companies to prioritize antiviral preparedness and response, encouraging the development of both preventive and therapeutic solutions
- Governments and international health organizations are allocating greater funding toward antiviral research, surveillance programs, and stockpiling of essential antiviral drugs to strengthen public health readiness against viral outbreaks
- This trend is also driving interest in repurposing existing antivirals for multiple indications and accelerating the regulatory approval processes for fast-track treatment deployment during pandemics
- The mounting prevalence of viral infections worldwide is reshaping healthcare priorities and positioning antiviral drug development as a critical area of pharmaceutical innovation and public health investment
